Manufacturer Provide Top Quality API Veterinary Medicine CAS123997-26-2 Eprinomectin
Introduction
Product Name: Eprinomectin
Other Name :4''R)-4''-(ACETYLAMINO)-4''-DEOXY-AVERMECTIN B1;Emamectin B1 Benzoate;EPRINOMECTIN VETRANAL;EprinomectinB1
C.A.S NO. :123997-26-2
Assay (%)(HPLC, Basis on drying):99%
Appearance:White Crystal Powder
MF:C50H75NO14
MW:914.1288
Melting Point :163-166°C (dec.)(lit.)
Density :1.23 g/mL at 25 °C (lit.)
Storage Condition: Keep in dark place,Sealed in dry,Room Temperature
Items | Specifications | Results |
Appearance | White to yellowish crystalline powder | Qualified |
Identification | Infrared Absorption | Qualified |
The retention times of the Component B1a peak and the Component B1b peak in the chromatogram of the Assay preparation correspond to those in the chromatogram of the standard preparation | Qualified |
Specific rotation | +132 °~ +140 ° | +137 ° |
Water | ≤2.0% | 0.3% |
Residue on ignition | ≤0.1% | 0.1% |
Heavy metals | ≤10ppm | 10ppm |
Residual solvents | Acetonitrile ≤0.005% | 0.003% |
Sum of all solvent ≤0.5% | 0.2% |
8a-oxo-B1a | ≤0.5% | 0.1% |
Related compounds | Related compounds with relative retentions of 0.23,0.93, and 1.16 correspond to B1a peak≤ 1.0% | 0.5% |
Related compounds | Impurity A ≤1.0% | 0.2% |
Impurity E ≤ 1.0% | 0.1% |
All other known impurities ≤0.5% | 0.2% |
Total unknown impurities≤ 1.0% | 0.3% |
Total impurities ≤5.0% | 1.3% |
Assay | Component B1a ≥90.0% | 93.1% |
Component B1a and Component B1b≥ 95.0% | 98.7% |
Function
Eprinomectin is moderately used in ruminants, mainly in pour-ons and injectables. So far it is not used in swine, poultry or horses. Use in cats as a spot-on (in combination with other actives) is still rather scarce. So far it is not used in dogs.
In most finished products, efficacy and safety depend not only on the amount of active ingredient(s) but also on their formulations (i.e. the type and amount of so-called inert ingredients), particularly in injectables and in topical pour-ons and spot-ons. These inert ingredients can significantly affect the pharmacokinetic behavior (e.g. absorption through the skin or from the injection site, distribution within the body, spreading throughout the body surface, etc.). Generic products usually contain the same amount of active ingredient(s) as the original product, but often in quite different formulations. In many cases, the curative (therapeutic) efficacy of the different formulations is quite comparable, but the protective (prophylactic) efficacy that determines the length of protection against re-infestations may be rather different.
China
